期刊
YEAR IN IMMUNOLOGY 2008
卷 1143, 期 -, 页码 123-150出版社
WILEY-BLACKWELL
DOI: 10.1196/annals.1443.016
关键词
RANK; RANKL; OPG; osteoclastogenesis; osteoimmunology; RANK-RANKL signaling; osteoporosis; rheumatoid arthritis; lymph node formation; mammary gland biology
Bone-related diseases, such as osteoporosis and rheumatoid arthritis, affect hundreds of millions of people worldwide and pose a tremendous burden to health care. By deepening our understanding of the molecular mechanisms of bone metabolism and bone turnover, it became possible over the past years to devise new and promising strategies for treating such diseases. In particular, three tumor necrosis factor (TNF) family molecules, the receptor activator of NF-kappa B (RANK), its ligand RANKL, and the decoy receptor of RANKL, osteoprotegerin (OPG), have attracted the attention of scientists and pharmaceutical companies alike. Genetic experiments revolving around these molecules established their pivotal role as central regulators of osteoclast development at-Ad osteoclast function. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast: development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology an(] disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据